Navigation Links
Researchers at LSTM part of the international team to sequence the tsetse genome
Date:4/25/2014

Researchers from LSTM are among those who have sequenced the genome of a species of tsetse fly (Glossina morsitans). The outcomes of this research will be invaluable to understanding more about the tsetse and other insect vector biology, knowledge which can be applied to improving the current vector control methods and may lead to more effective and affordable control strategies.

A paper summarising some of the findings will be published in the journal Science today, with more specific and in depth analyses of various aspects of tsetse biology being published as a collection of 10 papers within the PLOS family of journals.

The tsetse fly is the vector for African trypanosomiasis, a potentially fatal disease in people (sleeping sickness) and livestock (Nagana), throughout sub-Saharan Africa, with an estimated 70 million people at risk of infection. Unlike other disease vectors, such as mosquitoes and sandflies, both sexes of the tsetse fly feed exclusively on vertebrate blood, meaning that all tsetse are capable of spreading the disease. To deal with the nourishment issues arising from feeding exclusively on blood the tsetse has formed complex relationships with three different symbiotic bacteria. It is also unusual among insects as it gives birth to live young having evolved to lactate in order to provide nourishment to intrauterine offspring.

The work was carried out over a 10 year period following the formation of the International Glossina Genome Initiative in 2003. Around 146 scientists have contributed to the work, including members of the departments of Vector Biology, Parasitology and Clinical Sciences within LSTM, along with colleagues from around the world, with at least half of the contributors being from African institutions.

LSTM's Professor Mike Lehane was a member of the project leadership team and describes the significance of the work: "Human infections with African trypanosomes can be fatal if left untreated. It has not been possible to develop a vaccine for the disease due to the ability of trypanosomes to evade the mammalian immune system, this coupled with the fact that there are some significant side-effects and reports of growing resistance to current trypanocidal drug treatments means that vector control strategies remain the best hope to eliminate the disease.

"The work that has been carried out by such a large group of international researchers and scientists has not been without its challenges, but has given us detailed information on a wide range of aspects of tsetse biology. It has provided us with a vital research tool, which will be continually added to over time and may well lead to control strategies that can bring an end to suffering caused by the disease both in terms of the human cost as well as the economic losses due to affected livestock."


'/>"/>

Contact: Clare Bebb
c.bebb@liv.ac.uk
44-015-170-53135
Liverpool School of Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Oxygen diminishes the hearts ability to regenerate, researchers discover
2. Finnish team of researchers finds a mutation in a tumor of the jaw
3. Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches
4. Life stressors trigger neurological disorders, researchers find
5. Penn researchers find link between sleep and immune function in fruit flies
6. Penn Medicine researchers uncover hints of a novel mechanism behind general anesthetic action
7. CU researchers discover target for treating dengue fever
8. BUSM researchers find anti-seizure drug may reduce alcohol consumption
9. Researchers identify children with emotional behavior difficulties
10. Researchers identify similarities between HIV/AIDS and opioid addiction epidemics
11. Oxytocin, the love hormone, promotes group lying, according to Ben-Gurion U. researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... NJ (PRWEB) , ... April 28, 2017 , ... Horizon ... has affirmed the company’s credit rating of “A” and its outlook as “stable.” At ... if capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... New york (PRWEB) , ... April 28, 2017 ... ... pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice ... training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique ...
(Date:4/28/2017)... ... 2017 , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit ... at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical ... to donate. , “Women’s Hospital at Renaissance has been a collection partner for ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: